Business Wire

Clinical Review Demonstrates Cost-Effectiveness of Impella in High-Risk PCI and Cardiogenic Shock


To mark the five year anniversary of the study by Stretch, et al., on cost and outcomes trends for short-term mechanical circulatory support, Abiomed announces a comprehensive publication review of cost and comparative effectiveness of Impella in high-risk PCI and cardiogenic shock. The data, from a robust body of US and European evidence from 2004 - 2019, includes the PROTECT II FDA randomized controlled trial, data from the Centers for Medicare & Medicaid Services MedPAR database and more than 20 peer-reviewed clinical publications on cost-effectiveness. It demonstrates that Impella use in high-risk PCI (Protected PCI) and cardiogenic shock, when compared to intra-aortic balloon pump (IABP) or other therapies, is associated with improved patient outcomes and reduced costs. The review will be presented at upcoming meetings of interventional cardiologists and cardiac surgeons in Munich, Germany, and Phoenix, Arizona.

This press release features multimedia. View the full release here:

Multiple studies, including systematic reviews of multiple cost-effectiveness publications, demonstrate that Impella use is associated with a reduction in length of stay for patients, with a greater opportunity for benefit as the illness level increases. (Graphic: Business Wire)

Multiple studies, including systematic reviews of multiple cost-effectiveness publications, demonstrate that Impella use is associated with a reduction in length of stay for patients, with a greater opportunity for benefit as the illness level increases. (Graphic: Business Wire)

Key evidence of Impella's cost-effectiveness includes data on how:

  • Impella reduces mortality and cost
  • Impella reduces length of stay and readmissions
  • Impella reduces long-term health care costs

Impella Reduces Mortality and Cost

Several studies show that the use of percutaneous ventricular assist devices (PVADs), including Impella, is particularly cost-effective in cases of cardiogenic shock:

Impella Reduces Length of Stay and Readmissions

Several studies, including systematic reviews of multiple cost-effectiveness publications, demonstrate that Impella use is associated with a reduction in length of stay for patients, with a greater opportunity for benefit as the illness level increases1.

According to peer-reviewed published data, Impella use is associated with:

These findings are consistent in the United States and Europe. A retrospective cost-effectiveness analysis based on the USPella and Europella databases concluded that Impella is a cost-effective intervention compared with IABP for high-risk PCI patients (Roos, et al., Journal of Medical Economics, 2013).

As an example of Impella’s cost-effectiveness, the United Kingdom’s National Institute for Health Care and Excellence (NICE), one of the world’s most conservative regulatory bodies, confirmed the use of Impella in certain high-risk PCI patients.

“Sometimes trying to save costs by avoiding or delaying the use of innovative technologies sounds good, but you delay safe and effective therapy. Then the patients are sicker, and their outcomes are worse, which ends up being more costly for the patient and healthcare system. Using a better therapy up front can give you a better long-term outcome while reducing total costs,” said George Vetrovec, MD, professor, emeritus, at Virginia Commonwealth University.

Case Studies: Impella Reduces Long-term Health Care Costs

Because Impella enables the heart to rest and recover - while helping to restore native heart function - it may prevent the need for an implantable left ventricular assist device (LVAD) or a heart transplant, leading to an estimated $887,000 reduction in hospital charges over the period from 30 days pre-transplant to 180 days post-transplant discharge2. This makes native heart recovery one of the most cost-effective therapies in healthcare.

The case of Adam Millar illustrates the real-world benefit of native heart recovery. In 2018, Millar was 18 years old when Nima Aghili, MD, an interventional cardiologist at St. Anthony’s Central in Lakewood, Colorado, placed an Impella CP and Impella RP to recover Adam’s heart after he was diagnosed with atrial fibrillation and developed cardiogenic shock. At the time, Millar was a junior hockey player, and native heart recovery proved to be the best outcome for his health and future quality of life. Adam’s treatment was covered by United Healthcare.

“Before Impella recovered my heart, physicians considered me as a candidate for an implantable LVAD and a heart transplant. Both would have drastically decreased my quality of life,” said Millar. “If I received a heart transplant, I would have had a long recovery and taken auto-immune medication to avoid the rejection of the transplanted heart for the rest of my life.”

Impella also enables high-risk PCI patients to improve their native heart function through Impella-supported Protected PCI. The story of Jim Hoag illustrates how Protected PCI with Impella and complete revascularization enable better outcomes and improved quality of life for patients.

Jim, a 67-year-old grandfather, struggled with such extreme weakness and fatigue that he could barely walk from the parking lot to the athletic field to watch his grandsons play sports. He went to Spectrum Health in Grand Rapids, Michigan, where a diagnostic catheterization revealed severe blockages and poor heart function with an ejection fraction of 25%. Jim was referred to the advanced heart failure clinic where he was identified by the heart team as an appropriate candidate for Protected PCI. Drs. David Wohns and Kevin Wolschleger implanted the Impella 2.5 to support Jim's weak heart while they placed multiple stents.

Jim was discharged home one day later, and within two months his heart function had returned to near normal with an ejection fraction of 55%. Jim’s treatment was reimbursed by Medicare. Today, Jim feels better than he has in years, attended Abiomed's patient summit in Danvers, Massachusetts, this summer, and now climbs to the top of the stands to cheer on his grandchildren.

Cost- Effectiveness Compared to Other Therapies

Impella’s cost-effectiveness when compared to other related treatments, including LVADs, is validated based on an incremental cost-effectiveness ratio -- or ICER. ICER is a standard economic metric that represents the additional cost of one unit of a healthcare outcome, such as a quality-adjusted life year, gained by a healthcare intervention or strategy when compared with the next best alternative or standard of care. Amounts less than $100,000 are considered cost effective in the U.S., and less than $50,000 in most other countries. Impella’s ICER shows a reduction in costs of $135,000 per year in an emergent population3.

1 Nalluri, et al, Expert Review of Medical Devices, 2017; Aryana, et al, Heart Rhythm Society, 2014; Krenn, et al, SCAI, 2014; Maini, et al, Journal of Catheterization and Cardiovascular Interventions, 2014; Maini, et al, Expert Review of Pharmacoeconomics & Outcomes Research, 2014; Wohns et al, International Society for Minimally Invasive Cardiothoracic Surgery, 2014; Gregory, et al, American Health & Drug Benefits Journal, 2013; Gregory, et al, Journal of Managed Care Medicine, 2013; O’Neil,l et al, Journal of American College of Cardiology. USPella, 2013; Roos, et al, Journal of Medical Economics, 2013; Lamarche, et al, Journal of Thoracic and Cardiovascular Surgery, 2010

2 Milliman 2017 US Organ and Tissue Transplant Cost Estimates and Discussion

3 Maini et al, Journal of Catheterization and Cardiovascular Interventions, 2014


The Impella 2.5® and Impella CP® devices are U.S. FDA PMA approved to treat certain advanced heart failure patients undergoing elective and urgent percutaneous coronary interventions (PCI) such as stenting or balloon angioplasty, to re-open blocked coronary arteries. The Impella 2.5, Impella CP, Impella CP with SmartAssist®, Impella 5.0®, Impella LD®, and Impella 5.5™ with Smart Assist® are U.S. FDA approved heart pumps used to treat heart attack or cardiomyopathy patients in cardiogenic shock, and have the unique ability to enable native heart recovery, allowing patients to return home with their own heart. The Impella RP® is U.S. FDA approved to treat right heart failure or decompensation following left ventricular assist device implantation, myocardial infarction, heart transplant, or open-heart surgery. Impella is the most studied mechanical circulatory support device in the history of the FDA with real world clinical data on more than 100,000 patients and more than 550 peer-reviewed publications.

In Europe, the Impella 2.5, Impella CP and Impella CP with SmartAssist are CE marked for treatment of high-risk PCI and AMI cardiogenic shock patients for up to 5 days. Impella 5.0 and Impella LD are CE marked to treat heart attack or cardiomyopathy patients in cardiogenic shock for up to 10 days. The Impella 5.5™ with Smart Assist® is CE marked to treat heart attack or cardiomyopathy patients in cardiogenic shock for up to 30 days. The Impella RP is CE marked to treat right heart failure or decompensation following left ventricular assist device implantation, myocardial infarction, heart transplant, open-heart surgery, or refractory ventricular arrhythmia.

To learn more about the Impella platform of heart pumps, including their approved indications and important safety and risk information associated with the use of the devices, please visit


Based in Danvers, Massachusetts, USA, Abiomed, Inc. is a leading provider of medical devices that provide circulatory support. Our products are designed to enable the heart to rest by improving blood flow and/or performing the pumping of the heart. For additional information, please visit:

Abiomed, Impella, Impella 2.5, Impella 5.0, Impella LD, Impella CP, Impella RP, and Impella Connect are registered trademarks of Abiomed, Inc., and are registered in the U.S. and certain foreign countries. Impella BTR, Impella 5.5, Impella ECP, CVAD Study, and SmartAssist are pending trademarks of Abiomed, Inc.


This release contains forward-looking statements, including statements regarding development of Abiomed's existing and new products, the company's progress toward commercial growth, and future opportunities and expected regulatory approvals. The company's actual results may differ materially from those anticipated in these forward-looking statements based upon a number of factors, including uncertainties associated with development, testing and related regulatory approvals, including the potential for future losses, complex manufacturing, high quality requirements, dependence on limited sources of supply, competition, technological change, government regulation, litigation matters, future capital needs and uncertainty of additional financing, and other risks and challenges detailed in the company's filings with the Securities and Exchange Commission, including the most recently filed Annual Report on Form 10-K and Quarterly Report on Form 10-Q. Readers are cautioned not to place undue reliance on any forward-looking statements, which speak only as of the date of this release. The company undertakes no obligation to publicly release the results of any revisions to these forward-looking statements that may be made to reflect events or circumstances that occur after the date of this release or to reflect the occurrence of unanticipated events.

Contact information

Tom Langford
Director, Communications and Public Relations

Ingrid Goldberg Ward
Director, Investor Relations

About Business Wire

For more than 50 years, Business Wire has been the global leader in press release distribution and regulatory disclosure.

Subscribe to releases from Business Wire

Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.

Latest releases from Business Wire

Western Union Stands in Solidarity with Lebanon6.8.2020 23:47:00 EESTPress release

Western Union, a leader in cross-border, cross-currency money movement and payments, today announced that it is offering zero-feei international money transfers paid out in U.S. dollars to Lebanon, as the country grapples with its recent tragedy amidst other economic and pandemic related threats. This press release features multimedia. View the full release here: Western Union Stands in Solidarity with Lebanon; Money Transfers to Lebanon Zero-Fee Paid out in US Dollars (Graphic: Business Wire) “We stand in solidarity with the people of Lebanon as they confront this latest tragedy following the horrific explosion in Beirut on August 4. Our thoughts and prayers are with families of those injured and have lost their lives,” said Jean Claude Farah, President, Global Network, Western Union. Farah said: “We know the people of Lebanon will stand strong as they grapple with this latest issue amidst other pressures of economic and COVID-

Pacific Drilling Announces Second-Quarter 2020 Results; Pacific Sharav Awarded a New 10-Well Contract in U.S. Gulf of Mexico6.8.2020 23:04:00 EESTPress release

Pacific Drilling S.A. (NYSE: PACD) (“Pacific Drilling” or the “Company”) today reported results for the second quarter of 2020. Net loss for second-quarter 2020 was $87.4 million or $1.16 per diluted share, compared to net loss of $61.0 million or $0.81 per diluted share in first-quarter 2020. Pacific Drilling CEO Bernie Wolford commented, “In the second quarter, our crews and leadership continued to exemplify our commitment to safe and efficient operations, including adopting measures to manage risks associated with COVID-19 transmission, delivering exceptional results for our clients, efficiently preserving the value of our assets and significantly reducing overhead costs.” Mr. Wolford continued, “Although oil prices began to rebound during the second quarter, clients have generally reduced their drilling investments, as evidenced by Equinor’s decision to cancel the previously exercised third firm well for Pacific Khamsin, and Murphy’s decision to cancel the two well Mexico contract

Andersen Global Enters into Collaboration Agreement with CFA Afrique in Burkina Faso6.8.2020 16:30:00 EESTPress release

Andersen Global continues its West African expansion via a Collaboration Agreement with CFA Afrique, a tax and legal firm in Ouagadougou, marking the organization’s debut in Burkina Faso and further demonstrating Andersen Global’s growing presence on the African continent. Founded in 2004 and led by Office Managing Director Brahima Guire, CFA Afrique has grown to include nearly 20 total professionals advising a multitude of clients both regionally and internationally. The firm provides a variety of tax and legal services including tax consultancy and advisory, tax compliance, transfer pricing, corporate and commercial law and tax structuring. “Providing our clients with a tailor-made approach and the best-in-class solutions are our top priorities,” Brahima said. “Andersen Global’s expansion strategy and focus on providing clients with quality tax and legal services strengthens our competitive edge and will allow us to better serve our cross-border clientele. We look forward to seamless

New Conviva Data Shows Significant Drop in Ad Demand Despite Quality Improvements; Streaming Growth Normalizing After Pandemic Peak6.8.2020 16:00:00 EESTPress release

Conviva, the leader in global streaming media intelligence, released its quarterly State of Streaming report for Q2 2020 today, showing streaming video advertising saw a sharp decline in the past quarter with ad attempts in Q2 down 28% globally and 22% in the U.S. as compared to Q1 2020. The report also details the impact of COVID-19 with expanded regional benchmarks illustrating that while streaming continues to grow overall, it slowed in May and June as compared to its height in April when shelter-in-place orders drove streaming viewing up 81% year over year. This press release features multimedia. View the full release here: Conviva's State of Streaming Q2 Report (Graphic: Business Wire) Ad Demand Drops while Quality Improves While advertising demand dropped in Q2, due in part to a lack of sports, streaming ads saw significant improvements in overall quality. Viewers spent 38% less time waiting for an ad to start in Q2 as com

Wipro Collaborates with Intel to Drive Business Continuity6.8.2020 15:30:00 EESTPress release

Wipro Limited (NYSE: WIT, BSE: 507685, NSE: WIPRO), a leading global information technology, consulting and business process services company, today announced that it will join forces with Intel to enable Wipro's LIVE Workspace™, Wipro's digital workspace solution with the Intel vPro® platform. This joint collaboration will help customers drive business continuity by enabling remote IT support and solutions, as they seek to keep employees productive amid social distancing boundaries and other remote-work limitations that have become the new normal. Wipro integrated the Intel vPro® platform into LIVE Workspace™, a suite of digital workplace services to provide remote manageability of devices. This extends to users at home or in the office and provides enhanced protection and security against firmware-level attacks. The combined solution provides practical business continuity services to enable enterprises to rapidly design, deploy, and manage a true remote work experience. Intel recentl

Thales High Tech to Offer Thai Citizens One of the World’s Most Secure E-Passports6.8.2020 15:00:00 EESTPress release

Even though the COVID-19 health crisis has been severely disrupting the global travel industry, in the past few months the DGM Consortium has continued its close collaboration with MOFA. Global teams were working remotely to deliver the project, supporting the Thai Government’s ‘Thailand 4.0’ vision to develop an innovative, digital economy. This press release features multimedia. View the full release here: Thai passports (Photo: Thales) The new Thai e-passport project was delivered on the 8th of July to MOFA and launched in an official inauguration ceremony conducted on the 5th of August in the presence of Minister Don Pramudwinai, Minister of Foreign Affairs of Thailand. The Thai e-passport project is one of the largest passport programs for Thales worldwide, as it aims to provide Thai citizens superior technology and the highest possible level of security in a travel document. The newly designed 64-page biometric travel docu

In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.

Visit our pressroom